马雷辛1通过抑制NF-κB/Stat3/MAPK通路来预防败血症引起的急性肝损伤,减轻炎症
Shujun Sun1,2,3, Li Wang1,2,3, Jiamei Wang4
1Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Heliyon
|November 29, 2023
概括
马雷辛1 (MaR1) 在小鼠中有效治疗败血症引起的急性肝损伤 (SI-ALI). 这种omega-3衍生物减少炎症和细菌负载,改善生存率和肝功能.
科学领域:
- * 生物医学研究
- * 炎症和免疫学
- * 肝病学 肝病学是一门学科.
背景情况:
- * 败血症引起的急性肝损伤 (SI-ALI) 带来了重大治疗挑战.
- * 炎症反应是SI-ALI病理生理学的关键驱动因素.
- *马雷辛1 (MaR1) 是一种omega-3脂肪酸衍生物,具有抗炎性质.
研究的目的:
- * 在小鼠模型中研究MaR1对结和穿刺 (CLP) 诱导的SI-ALI的治疗效果.
- *阐明MaR1减轻SI-ALI的潜在机制.
主要方法:
- *小鼠接受了CLP手术以诱导SI-ALI.
- *小鼠接受了低剂量MaR1,高剂量MaR1或无菌正常盐水 (NS) 的静脉注射.
- *评估结果包括生存率,体重变化,肝功能标志物,细菌负载,中性粒细胞透和炎症性细胞因子水平.
主要成果:
- * MaR1的使用显著改善了剂量依赖的7天生存率.
- * MaR1 治疗减少了腹膜洗液和血液中的细菌负载.
- * MaR1降低了促炎性细胞因子 (TNF-α,IL-6,IL-1β) 和中性粒细胞透,同时增加了抗炎性IL-10.
- * MaR1在败血症小鼠中恢复了肝功能.
结论:
- * MaR1有效地减轻与败血症相关的肝损伤.
- * MaR1表明在治疗SI-ALI时具有临床应用的潜力.
- * 这项研究为MaR1在抗击败血症引起的炎症中的分子机制提供了新的见解.
相关概念视频
NF-κB-dependent Signaling Pathway
7.4K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.4K
The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K


